QSAM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
QSAM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
QSAM Biosciences's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-180.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-3,560.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for QSAM Biosciences's EPS without NRI or its related term are showing as below:
QSAM Biosciences's EPS (Diluted) for the three months ended in Dec. 2023 was $-180.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3,560.00.
QSAM Biosciences's EPS (Basic) for the three months ended in Dec. 2023 was $-180.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3,560.00.
The historical data trend for QSAM Biosciences's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QSAM Biosciences Annual Data | |||||||||||||||||||||
Trend | Mar14 | Mar15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EPS without NRI | Get a 7-Day Free Trial | -12.39 | -40.44 | -17.01 | -5,381.18 | -3,380.00 |
QSAM Biosciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EPS without NRI | Get a 7-Day Free Trial | -1,399.94 | -1,800.00 | -860.00 | -720.00 | -180.00 |
For the Biotechnology subindustry, QSAM Biosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, QSAM Biosciences's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where QSAM Biosciences's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3,560.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QSAM Biosciences (OTCPK:QSAM) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of QSAM Biosciences's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Adam King | officer: Chief Financial Officer | 9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759 |
Link Jr. Charles J | director | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010 |
Adriann Sax | director | 7 DORSET COURT,, EAST BRUNSWICK, NJ 08816 |
David Charles Link | director | 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104 |
Douglas R Baum | director, officer: CEO & Director | 5000 RAFFEE COVE, AUSTIN TX 78731-1132 |
C Richard Piazza | director, officer: Executive Chairman | 2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3 |
Checkmate Strategic Capital Holdings, Llc | other: Member of 13(d) 10% owner grp | 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101 |
Checkmate Strategic Capital 2, Llc | 10 percent owner, other: See Explanation of Responses | 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101 |
Checkmate Capital Group, Llc | 10 percent owner, other: Member of 13(d) 10% owner grp | 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101 |
Charles Thomas Paschall | other: Member of 13(d) 10% owner grp | 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101 |
Christopher M. Nelson | director, officer: General Counsel | 420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480 |
Scott W. Whitney | director, other: Former Director | 96 WINDSOR DRIVE, PINE BROOK NJ 07058 |
Kevin Bolin | director, officer: Former Chairman & CEO | 1081 ROSEDALE DRIVE, ATLANTA GA 30306 |
Tristan Peitz | director, other: Former Director | C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480 |
Joel David Mayersohn | director | 350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301 |
From GuruFocus
By Marketwired Marketwired • 05-04-2021
By Marketwired • 08-16-2023
By sperokesalga sperokesalga • 04-26-2023
By GuruFocusNews GuruFocusNews • 12-01-2021
By ACCESSWIRE ACCESSWIRE • 03-01-2023
By sperokesalga sperokesalga • 05-16-2023
By Marketwired Marketwired • 02-12-2021
By Stock market mentor Stock market mentor • 01-23-2023
By GuruFocusNews GuruFocusNews • 02-02-2022
By Marketwired Marketwired • 01-28-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.